A metabolomics approach for therapy response in breast cancer

Pedro Sanchez Rovira
Complejo Hospitalario De Joen, Spain

Due to its broad clinical heterogeneity, the treatment of breast cancer is based on a wide variety of protocols. However, only a fraction of patients will show a beneficial response. The discovery of biomarkers which enable the classification of responders and non-responders patients may have important implications to treatment protocols and outcomes. In this study, we carried out a metabolomic profiling of 46 serum samples of breast cancer patients at diagnostic to identify potential biomarker candidates that can predict response to neoadjuvant chemotherapy. To this end, we analyzed the samples using liquid chromatography couple to high resolution mass spectrometry LC-HRMS and the data matrix obtained was subjected to univariate and multivariate statistical analysis.

Biography

Pedro Sanchez-Rovira has completed his PhD from Sevilla University and Postdoctoral studies from Córdoba University School of Medicine. He is the Director of Oncology Unit in Jaen Hospital. He has published more than 75 papers in reputed journals and has been serving as an Editorial-Board Member of repute.

oncopsr@yahoo.es